Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bendroflumethiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendroflumethiazide SCHEMBL3359694 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL44537 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL26016 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumetazide SCHEMBL29742733 | 0.93 | ALDH1A1 (0.86) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL28086384 | 0.92 | LMNA (0.85) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| SCHEMBL13823288 | 0.87 | ALDH1A1 (0.76) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL16222867 | 0.86 | ALDH1A1 (0.73) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| SCHEMBL19167246 | 0.84 | ALDH1A1 (0.73) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| Bendroflumethiazide SCHEMBL10380009 | 0.84 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4ECYP3A4CA2 | |
| SCHEMBL13815372 | 0.84 | ALDH1A1 (0.72) | ALDH1A1LMNAKDM4ECYP3A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544711-B2 | Use of nitroderivatives in urinary incontinence | NICOX S.A. (FR) | 2009-06-09 | — | — | US | disclosed |
| US-20050101661-A1 | Use of nitroderivatives in urinary incontinence | NICOX S.A. (FR) | 2005-05-12 | — | — | US | disclosed |
| EP-1473288-A1 | Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases | Nicox S.A. (FR) | 2004-11-03 | — | — | EP | disclosed |
| EP-1437132-A1 | Use of nitric ester derivatives in the manufacture of a medicament for the treatment of gastrointestinal tumors | Nicox S.A (FR) | 2004-07-14 | — | — | EP | disclosed |
| US-20040082652-A1 | Nitric ester derivatives and their use in treating gastrointestinal tumors | NICOX S.A. | 2004-04-29 | — | — | US | disclosed |
| EP-0931065-A2 | NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES | NICOX S.A. (FR) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009948-A2 | NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES | NICOX S.A. (FR) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082652-A1 | Nitric ester derivatives and their use in treating gastrointestinal tumors | NOS1, PTGER1, NOS3 | ALDH1A1 711/4885LMNA 910/4885KDM4E 3182/4885 |
| US-20050101661-A1 | Use of nitroderivatives in urinary incontinence | NR0B1, NOX1, AKR1C1 | ALDH1A1 321/4885LMNA 1329/4885KDM4E 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.